Ofichem has announced the consolidation of its brands — Ofichem BV, Ofipharma, Ofimedicine, Labatorium Ofichem, Ofichem Uppsala and Avivia — into one family-owned CDMO and pharmaceutical supplier.
Since April 1st, all business units have been operating under the Ofichem trading name. The brand said that the move was in response to pharmaceutical and biotech companies increasingly looking to reduce complexity by working with fewer, more integrated partners that can support them across the lifecycle of their drug.
The decision brings together Ofichem’s capabilities across drug substance, drug product and sourcing and distribution into one integrated offering, giving customers a more connected view of the organisation and simplifying their engagement.
The company stressed that it would maintain the same quality, compliance and responsiveness customers rely on.
“Over time, we’ve built a business with real depth across API, drug substance, drug product and supply,” said Weite Oldenziel, CEO of Ofichem.
What has been less visible is how those capabilities come together. Combining all brands under the Ofichem umbrella makes that clear as we continue to support our customers in a more connected and consistent way.
“This is not a change to what we do, but to how clearly we present it,” he added.
Our customers can expect the same reliability and flexibility, now with greater visibility of our comprehensive support as we strive to give every medicine the best chance of fulfilling its potential.
The move also enhances Ofichem’s position as a European-based CDMO partner by providing regulatory expertise, supply chain reliability and fostering closer collaboration in a market increasingly focused on security, transparency and control.
